KR900018085A - 허혈방지제로서의 2- 피페리디노-1- 알칸올 유도체 - Google Patents

허혈방지제로서의 2- 피페리디노-1- 알칸올 유도체 Download PDF

Info

Publication number
KR900018085A
KR900018085A KR1019900006989A KR900006989A KR900018085A KR 900018085 A KR900018085 A KR 900018085A KR 1019900006989 A KR1019900006989 A KR 1019900006989A KR 900006989 A KR900006989 A KR 900006989A KR 900018085 A KR900018085 A KR 900018085A
Authority
KR
South Korea
Prior art keywords
hydrogen
alkyl
compound
independently
hydroxy
Prior art date
Application number
KR1019900006989A
Other languages
English (en)
Other versions
KR920004138B1 (ko
Inventor
레오 제나르드 버트랜드
Original Assignee
제이. 트레버 럼
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이. 트레버 럼, 화이자 인코포레이티드 filed Critical 제이. 트레버 럼
Publication of KR900018085A publication Critical patent/KR900018085A/ko
Application granted granted Critical
Publication of KR920004138B1 publication Critical patent/KR920004138B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Abstract

내용 없음

Description

허혈방지제로서의 2-피페리디노-1-알칸올 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 하기 일반식(Ⅰ)의 화합물 또는 그의 약제학적으로 허용가능한 산 부가염.
    상기식에서, R은 H, (C1-C6)알킬, (C2-C6)알케닐 또는 (C2-C6)알키닐이고;Q는 S 또는 CH=CH이며;X는 수소, (C1-C3)알킬, 할로, OR1, OCOR1, CO2R1, SR1, NHR1, NHCOR1, CONH2또는 CN이고;R1은 수소 또는 (C1-C3)알킬이며;Y 및 Y1은 함께 취해져 이거나;또는 Y 및 Y1은 별개로 취해져 Y가 수소 또는 OH이고, Y1이이며;n은 0,1,2 또는 3이고;m은 0,1,2,3 또는 4이며;Q1은 독립적으로 상기 정의한 바와 같은 Q의 값이고;X1은 독립적으로 상기 정의한 바와 같은 X의 값이며;및 Z는 O,S,SO 또는 SO2이다.
  2. 제1항에 있어서, R이의 1S*,2S*상대 입체화학을 갖는 메틸인 화합물.
  3. 제2항에 있어서, Q가 CH=CH이고, X가 4-하이드록시이며, Y 및 Y1이 별개의 취해진 화합물.
  4. 제3항에 있어서, Y가 H 또는 OH이고, Y1이 벤질인 화합물.
  5. 하기 일반식(Ⅱ)의 화합물 또는 그의 약제학적으로 허용가능한 산 부가염.
    상기식에서, D는이고;R은 H, (C1-C6)알킬, (C2-C6)알케닐 또는 (C2-C6)알키닐이고;Q는 S 또는 CH=CH이며;X는 수소, (C1-C3)알킬, 할로, OR1, OCOR1, CO2R1, SR1, NHR1, NHCOR1, CONH2또는 CN이고;R1은 수소 또는 (C1-C3)알킬이며;Y2및 Y3는 함께 취해져이거나;또는 Y2및 Y3는 별개로 취해져 Y2가 수소 또는 OH이고, Y3가이며;Y9는이고;Q1은 독립적으로 상기 정의한 바와 같은 Q의 값이고;X1은 독립적으로 상기 정의한 바와 같은 X의 값이고;n은 0,1,2 또는 3이며;M은 0,1,2,3 또는 4이다.
  6. 제5항에 있어서, Q가 CH=CH이고, X가 페릴고리의 4-위치에서 치환되며, 하이드록시, 플루오로, 또는 클로로이고, D가이며, Y2및 Y3가 별개로 취해진 화합물.
  7. 제6항에 있어서, R이 수소이고, X가 하이드록시이며, Y3가 벤질, 2-페닐에틸 또는 3-페닐프로필인 화합물.
  8. 제7항에 있어서, R이의 1S*,2S*상대 입체화학을 갖는 메틸인 화합물.
  9. 하기 일반식(Ⅲ)의 화합물 또는 그의 약제학적으로 허용가능한 산 부가염.
    상기식에서, R은 H, (C1-C6)알킬, (C2-C6)알케닐 또는 (C2-C6)알키닐이고;Q 및 Q1은 각각 독립적으로으로 S 또는 CH=CH이며;X 및 X은 각각 독립적으로 H, (C1-C3)알킬, 할로, OR1, OCOR1, CO2R1, SR1, NHR1, NHCOR1, CONH2또는 CN이고;R1은 H 또는 (C1-C3)알킬이며;Y4은 H이고;Z는 O,S,SO 또는 SO2이다.
  10. 제9항에 있어서, Y4가 수소이고, Q가 CH=CH이며, R이 메틸이고, X가의 1S*,2S*상대 입체화학을 갖는 4-하이드록시인 화합물.
  11. 하기 일반식(Ⅳ)의 화합물.
    상기식에서, A 및 B는 함께 취해져 산소이거나, 또는 A 및 B가 별개로 취해져 A가 수소이고, B가 하이드록시이며;R은 수소, (C1-C6)알킬, (C2-C6)알케닐 또는 (C2-C6)알키닐이고;Q는 S 또는 CH=CH이며;X2는 수소, (C1-C3)알킬, 할로, OR1, OCOR1, CO2R1, SR1, NHR1, NHCOR1, CONH2또는 CN이고;R1은 수소 또는 (C1-C3)알킬이며;R2는 통상의 하이드록시 또는 머캅탄 보호그룹이고;R3는 통상의 아미노 보호 그룹이며;Y5및 Y6는 함께 취해져이거나;또는 Y5및 Y6는 별개로 취해져 Y5가 수소 또는 OH이고, Y6가이거나 또는 Y5가 수소이고 Y6가이고;n은 n은 0,1,2 또는 3이고;m은 0,1,2,3 또는 4이고;Q1은 독립적으로 상기 정의한 바와 같은 Q의 값이고;X3은 독립적으로 상기 정의한 바와 같은 X2의 값이며;및 Z는 O,S,SO 또는 SO2이고;단, A 및 B가 별개로 취해질때, X2및 X3중 어느 하나는 OR2, SR2, NR1R3이다.
  12. 하기 일반식(Ⅴ)의 화합물.
    상기식에서, A 및 B는 함께 취해져 산소이거나, A 및 B가 별개로 취해져 A가 수소이고, B가 하이드록시이며; E는이고;R은 H, (C1-C6)알킬, (C2-C6)알케닐 또는 (C2-C6)알키닐이고;Q는 S 또는 CH=CH이며;X2는 수소, (C1-C3)알킬, 할로, OR1, OCOR1, CO2R1, SR1, NHR1, NHCOR1, CONH2또는 CN이고;R1은 수소 또는 (C1-C3)알킬이며;R2는 통상의 하이드록시 또는 머캅탄 보호그룹이고;Y7및 Y8는 함께 취해져이거나;또는 Y7및 Y8는 별개로 취해져 Y7이 OH이고, Y8이이며; Y10은이고;Q1은 독립적으로 상기 정의한 바와 같은 Q의 값이고;X3은 독립적으로 상기 정의한 바와 같은 X2의 값이고;n은 0,1,2 또는 3이며;m은 0,1,2,3 또는 4이고;단, A 및B가 별개로 취해질때, X2및 X3중 적어도 하나는 OR2, SR2, NR1R3이다.
  13. 하기 일반식(Ⅵ)의 화합물.
    상기식에서, A 및 B는 함께 취해져 산소이거나, A 및 B가 별개로 취해져 A가 수소이고, B가 하이드록시이며;R은 H, (C1-C6)알킬, (C2-C6)알케닐 또는 (C2-C6)알키닐이고;Q는 Q1은 각각 독립적으로으로 S 또는 CH=CH이며;X2및 X3은 각각 독립적으로 H, (C1-C3)알킬, 할로, OR1, OCOR1, CO2R1, SR1, NHR1, NHCOR1, CONH2또는 CN이고;R1은 H 또는 (C1-C3)알킬이며;R2는 통상의 OH 또는 SH 보호그룹이고;R3는 통상의 의미노 보호그룹이며;Y4은 H이고;Z는 O,S,SO 또는 SO2이며;단, A 및 B가 별개로 취해질때, X2및 X3중의 적어도 하나는 OR2, SR2또는 NR1R3이다.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900006989A 1989-05-17 1990-05-16 허혈방지제로서의 2-피페리디노-1-알칸올 유도체 KR920004138B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8902176 1989-05-17
USPCT/US89/02176 1989-05-17
PCT/US1989/002176 WO1990014087A1 (en) 1989-05-17 1989-05-17 2-piperidino-1-alkanol derivatives as antiischemic agents
USPCT/US90/00292 1990-01-16
US9000292 1990-01-16
PCT/US1990/000292 WO1990014088A1 (en) 1989-05-17 1990-01-16 2-piperidino-1-alkanol derivatives as antiischemic agents

Publications (2)

Publication Number Publication Date
KR900018085A true KR900018085A (ko) 1990-12-20
KR920004138B1 KR920004138B1 (ko) 1992-05-25

Family

ID=22215027

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900006989A KR920004138B1 (ko) 1989-05-17 1990-05-16 허혈방지제로서의 2-피페리디노-1-알칸올 유도체

Country Status (19)

Country Link
US (3) US5185343A (ko)
JP (1) JPH0735368B2 (ko)
KR (1) KR920004138B1 (ko)
CN (1) CN1032209C (ko)
AT (1) ATE150021T1 (ko)
BR (1) BR1101053A (ko)
CZ (1) CZ284342B6 (ko)
DE (1) DE69030134T2 (ko)
DK (1) DK0398578T3 (ko)
FI (1) FI113645B (ko)
HK (1) HK1000468A1 (ko)
IL (2) IL114174A (ko)
NO (1) NO180268C (ko)
PH (1) PH31464A (ko)
PL (1) PL163580B1 (ko)
RU (1) RU2029769C1 (ko)
SK (1) SK232890A3 (ko)
WO (2) WO1990014087A1 (ko)
ZA (1) ZA903741B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT65836A (en) * 1991-04-18 1994-07-28 Pfizer Process for producing phenol-esters of 1-(hydroxy-phenyl)-2-piperidino-1-alkanol derivatives and pharmaceutical compositions containing them
US5594007A (en) * 1991-04-18 1997-01-14 Pfizer Inc. Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
US5710168A (en) * 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
US6255322B1 (en) * 1992-06-19 2001-07-03 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
US5436255A (en) * 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
ATE183184T1 (de) * 1994-01-31 1999-08-15 Pfizer Neuroprotektive chroman verbindungen
KR100224961B1 (ko) * 1994-08-18 1999-10-15 디. 제이. 우드 신경보호성 3-(피페리디닐-1)-크로만-4,7-디올 및 1-(4-하이드로페닐)-2-(피페리디닐-1)-알칸올 유도체
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
IL122649A (en) * 1995-08-11 2001-08-26 Pfizer (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents
IL145209A0 (en) * 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
MXPA04000737A (es) 2001-07-24 2004-07-08 Richter Gedeon Vegyeszet Derivados de piperidina como antagonistas receptores de nmda.
WO2005030720A1 (ja) * 2003-09-25 2005-04-07 Shionogi & Co., Ltd. Ｎｍｄａ受容体拮抗作用を有するピペリジン誘導体
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
WO2006075004A2 (en) * 2005-01-13 2006-07-20 Neurosearch A/S 3, 8 - substituted 8-aza-bicyclo[3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
FR2919353B1 (fr) 2007-07-23 2014-02-14 Alstom Power Hydraulique Machine hydraulique comprenant des moyens d'injection d'un ecoulement preleve d'un ecoulement principal
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
US20140322315A1 (en) 2011-11-22 2014-10-30 The Regents Of The University Of California Cysteamine and/or cystamine for treating ischemic injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB963639A (en) * 1960-10-20 1964-07-15 Arnold Heyworth Beckett New piperidine derivatives and processes for preparing the same
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
US3136778A (en) * 1961-02-27 1964-06-09 Parke Davis & Co 1-[(omega oxy-lower alkyl)]-2-methyl-3-phenyl-3-propionyloxy-pyrrolidines
BE615410A (ko) * 1961-03-22
FR5733M (ko) * 1966-09-27 1968-01-22
JPS532474A (en) * 1976-06-26 1978-01-11 Yoshitomi Pharmaceut Ind Ltd Aminoketone derivatives
JPS5359675A (en) * 1976-11-08 1978-05-29 Yoshitomi Pharmaceut Ind Ltd Aminoalcohol derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
US4366154A (en) * 1981-11-09 1982-12-28 Sandoz, Inc. Tropyl derivatives
FR2546166B1 (fr) * 1983-05-19 1985-10-25 Synthelabo Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique
JPS60228460A (ja) * 1984-04-27 1985-11-13 Nippon Iyakuhin Kogyo Kk ピペリジノプロパノ−ル誘導体の製法
JPS6136262A (ja) * 1984-07-26 1986-02-20 Nippon Iyakuhin Kogyo Kk ピペリジノ−プロパノンもしくは−プロパノール誘導体及びその製法

Also Published As

Publication number Publication date
NO180268C (no) 1997-03-19
DE69030134T2 (de) 1997-06-19
CN1032209C (zh) 1996-07-03
ZA903741B (en) 1991-12-24
IL114174A (en) 1996-06-18
US5338754A (en) 1994-08-16
WO1990014087A1 (en) 1990-11-29
BR1101053A (pt) 2000-03-28
PL285190A1 (en) 1991-03-25
FI915403A0 (fi) 1991-11-15
CZ232890A3 (cs) 1998-07-15
KR920004138B1 (ko) 1992-05-25
US5185343A (en) 1993-02-09
JPH0735368B2 (ja) 1995-04-19
CZ284342B6 (cs) 1998-10-14
SK279476B6 (sk) 1998-11-04
HK1000468A1 (en) 1998-03-27
DK0398578T3 (da) 1997-10-13
US5391742A (en) 1995-02-21
WO1990014088A1 (en) 1990-11-29
NO180268B (no) 1996-12-09
NO914485L (no) 1991-11-15
FI113645B (fi) 2004-05-31
RU2029769C1 (ru) 1995-02-27
NO914485D0 (no) 1991-11-15
IL94357A (en) 1996-08-04
IL114174A0 (en) 1995-10-31
PL163580B1 (pl) 1994-04-29
JPH035478A (ja) 1991-01-11
SK232890A3 (en) 1998-11-04
PH31464A (en) 1998-11-03
DE69030134D1 (de) 1997-04-17
CN1047291A (zh) 1990-11-28
ATE150021T1 (de) 1997-03-15

Similar Documents

Publication Publication Date Title
KR900018085A (ko) 허혈방지제로서의 2- 피페리디노-1- 알칸올 유도체
NO163566C (no) 1,5-benzothiazepinderivater som er anvendelige som utgangsmaterialer ved fremstilling av nye, terapeutisk aktive 8-klor-1,5-benzothiazepinderivater.
KR870008889A (ko) 베타-락탐화합물, 및 그의 제조 방법
AU6129890A (en) Novel compounds
NO904377D0 (no) Tricykliske karbapenemforbindelser.
AU8864191A (en) Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
AU3182793A (en) Imidazole derivatives having anti-hiv activity
PT90986A (pt) Processo para a preparacao de esteres de estramustina e de composicoes farmaceuticas que os contem
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
AU5157679A (en) Isatin derivatives
IE873182L (en) Triazaspirodecanylmethylindolone derivatives
PT92147A (pt) Processo para a preparacao de derivados de pirrolidina
DE69204480T2 (de) Anilinderivate und Verfahren zu ihrer Herstellung.
AU3626189A (en) New derivatives of phenothiazine, their preparation and the compositions which contain them
PT92175A (pt) Processo para a preparacao de 3-amino-sidnoniminas substituidas e de produtos intermediarios farmacologicamente activos
KR920002564A (ko) N-알킬 티아졸리딘 유도체
ES2023760A6 (es) Procedimiento para la preparacion de derivados benzotiazinicos.
DE68918298T2 (de) Antibiotikum-Derivat.
ES2011986A6 (es) Procedimiento para preparar derivados de ergolina.
FI962714A (fi) Menetelmä terapeuttisesti käyttökelpoisten naftyridiinijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060502

Year of fee payment: 15

LAPS Lapse due to unpaid annual fee